$250.00
PT-141, also known as Bremelanotide, is a melanocortin receptor agonist studied for its interaction with central nervous system signaling pathways. In controlled research environments, PT-141 is evaluated for its influence on melanocortin receptor activity, behavioral response modeling, and neuroendocrine signaling dynamics.
Unlike PDE-based compounds, PT-141 acts centrally through melanocortin receptor pathways, making it a compound of interest in neurobehavioral and hypothalamic signaling research.
Research Name: PT-141
Alias: Bremelanotide
Category: Melanocortin receptor agonist
Primary Research Focus: Neurobehavioral signaling, melanocortin pathway modulation, central nervous system modeling
Format: Lyophilized powder
Upon reconstitution with an appropriate volume of bacteriostatic water, final concentration will vary depending on total diluent added. Researchers calculate concentration using the standard formula:
Total mg in vial ÷ Total mL added = mg per mL
For U-100 insulin syringes:
1 mL = 100 units
Units required are determined by dividing the desired mg amount by the final mg/mL concentration.
PT-141 is studied for its potential influence on:
Melanocortin Receptor Activity
MC3R / MC4R pathway modeling
Hypothalamic signaling dynamics
Central behavioral-response frameworks
Neuroendocrine Signaling
Dopaminergic pathway interaction
Autonomic nervous system response modeling
Hormonal communication studies
Behavioral & Motivational Research
Arousal pathway analysis
Reward-system signaling evaluation
CNS activation trends
Its mechanism centers on receptor-mediated central signaling rather than vascular modulation, distinguishing it from peripheral vasodilatory compounds.
Within structured research environments, investigators may observe:
Dose-dependent variables
Flushing
Nausea
Blood pressure variability
Neurologic observations
Headache
Increased alertness
Transient dizziness
Localized observations
Injection-site irritation
Temporary sensitivity
Monitoring intensity is often higher during early protocol phases due to central receptor engagement.
Administration Frequency: Varies by study design (often episodic rather than daily)
Common Study Duration: Short-term or event-based modeling
Titration Strategy: Incremental adjustments to evaluate receptor response
Researchers may exercise caution when combining PT-141 with other CNS-active or melanocortin-modulating compounds to prevent additive signaling effects.
Store lyophilized vial in a cool, dry environment.
Refrigerate after reconstitution.
Maintain sterile laboratory handling procedures at all times.
